

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase Ib V-FAST trial is evaluating CPX-351 in combination with which of the following targeted agents?**
 - Venetoclax
 - Midostaurin
 - Enasidenib
 - All of the above
- 2. Which of the following patients with acute myeloid leukemia (AML) are candidates for treatment with CPX-351?**
 - Those with newly diagnosed primary AML with FLT3 mutations
 - Those with relapsed/refractory primary AML
 - Those with newly diagnosed therapy-related AML
 - Those with heavily pretreated therapy-related del(5q) AML
- 3. Which of the following is the most common antecedent cancer for therapy-related AML?**
 - Cervical cancer
 - Thyroid cancer
 - Prostate cancer
 - Breast cancer
- 4. What is the approximate incidence of therapy-related AML relative to the total population of patients with AML?**
 - <1%
 - 8%
 - 36%
- 5. Which of the following statements best describes the toxicity profiles of CPX-351 versus conventional 7 + 3 in the Phase III trial for older patients with newly diagnosed high-risk or secondary AML?**
 - Incidence of Grade 3 to 5 events was significantly higher with CPX-351
 - Incidence of Grade 3 to 5 events was significantly higher with 7 + 3
 - Incidence of Grade 3 to 5 events was similar with both regimens